Zoledronic acid acutely increases sclerostin serum levels in women with postmenopausal osteoporosis.

Abstract

CONTEXT Sclerostin is a circulating inhibitor of the Wnt-signaling pathway produced by osteocytes, which acts as a negative regulator of bone formation. Effects of zoledronic acid on sclerostin serum levels in postmenopausal osteoporosis are unknown. OBJECTIVE The purpose of this study was to evaluate sclerostin serum levels after zoledronic acid… (More)
DOI: 10.1210/jc.2012-4039

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics